Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo PO QD Clear all
Completed Phase 3 Interventional Results available

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

NCT03416179
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, cytarabine, HSCT
Drug · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 5, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional Results available

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

NCT04947579
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
CC-99677, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Flagstaff, Arizona • Gilbert, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients

NCT00675987
View directory record Official record
Conditions
Obesity, Hypertension, Hyperglycemia
Interventions
losartan, Placebo control
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Little Rock, Arkansas • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 5, 2026, 2:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

NCT01064648
View directory record Official record
Conditions
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
Interventions
Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
230
States / cities
Rogers, Arkansas • Antioch, California • Burbank, California + 148 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT02521285
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Reversing Corticosteroid Induced Memory Impairment

NCT01142310
View directory record Official record
Conditions
Memory Impairment
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

NCT00513461
View directory record Official record
Conditions
Adult Primary Liver Cancer, Hepatitis C Infection
Interventions
S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography
Drug · Other
Lead sponsor
Chao Family Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine Versus Placebo in Chronic Low Back Pain

NCT00408876
View directory record Official record
Conditions
Back Pain Without Radiation
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fort Myers, Florida • Orlando, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Lovastatin in Treating Patients At High Risk of Melanoma

NCT00462280
View directory record Official record
Conditions
Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions
lovastatin, placebo, biopsy, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Orange, California • Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 5, 2026, 2:52 PM EDT
Not listed Phase 4 Interventional

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

NCT02294305
View directory record Official record
Conditions
Social Anxiety Disorder, Major Depressive Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

NCT01236547
View directory record Official record
Conditions
Thyroid Gland Anaplastic Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride, Placebo Administration
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
130
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Not applicable Interventional Results available

Trial of Montelukast for Treatment of Acute Bronchiolitis

NCT00863317
View directory record Official record
Conditions
Bronchiolitis
Interventions
montelukast sodium, sucrose
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Months to 12 Months
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632
View directory record Official record
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 5, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters

NCT06009926
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm
Interventions
Acetaminophen, Biospecimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement, Placebo Administration, Questionnaire Administration, Training
Drug · Procedure · Dietary Supplement + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 5, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

NCT00414960
View directory record Official record
Conditions
Lung Cancer
Interventions
Enzastaurin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 5, 2026, 2:52 PM EDT
Withdrawn Phase 2 Interventional

Dasatinib for the Treatment of Moderate and Severe COVID-19

NCT04830735
View directory record Official record
Conditions
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Dasatinib Anhydrous, Placebo Administration
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Adolescents With Schizophrenia

NCT00102063
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg, Placebo tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 5, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

NCT04575610
View directory record Official record
Conditions
COVID-19
Interventions
PF-06650833, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

NCT01950403
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease
Interventions
linaclotide acetate, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

NCT01381718
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Fatigue, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
modafinil, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 19 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 5, 2026, 2:52 PM EDT
Completed Phase 1 Interventional

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

NCT00454298
View directory record Official record
Conditions
Osteoarthritis
Interventions
AGG-523 (Aggrecanase Inhibitor)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Newton, Massachusetts • Winchester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2009 · Synced Oct 5, 2026, 2:52 PM EDT